Literature DB >> 32554601

Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer.

Eric L Bolf1,2, Noelle E Gillis1,2, Cole D Davidson1,2, Princess D Rodriguez3, Lauren Cozzens1, Jennifer A Tomczak1, Seth Frietze2,3, Frances E Carr4,2.   

Abstract

The thyroid hormone receptor beta (TRβ), a key regulator of cellular growth and differentiation, is frequently dysregulated in cancers. Diminished expression of TRβ is noted in thyroid, breast, and other solid tumors and is correlated with more aggressive disease. Restoration of TRβ levels decreased tumor growth supporting the concept that TRβ could function as a tumor suppressor. Yet, the TRβ tumor suppression transcriptome is not well delineated and the impact of TRβ is unknown in aggressive anaplastic thyroid cancer (ATC). Here, we establish that restoration of TRβ expression in the human ATC cell line SW1736 (SW-TRβ) reduces the aggressive phenotype, decreases cancer stem cell populations and induces cell death in a T3-dependent manner. Transcriptomic analysis of SW-TRβ cells via RNA sequencing revealed distinctive expression patterns induced by ligand-bound TRβ and revealed novel molecular signaling pathways. Of note, liganded TRβ repressed multiple nodes in the PI3K/AKT pathway, induced expression of thyroid differentiation markers, and promoted proapoptotic pathways. Our results further revealed the JAK1-STAT1 pathway as a novel, T3-mediated, antitumorigenic pathway that can be activated in additional ATC lines. These findings elucidate a TRβ-driven tumor suppression transcriptomic signature, highlight unexplored therapeutic options for ATC, and support TRβ activation as a promising therapeutic option in cancers. IMPLICATIONS: TRβ-T3 induced a less aggressive phenotype and tumor suppression program in anaplastic thyroid cancer cells revealing new potential therapeutic targets. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32554601      PMCID: PMC7541631          DOI: 10.1158/1541-7786.MCR-20-0282

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  48 in total

Review 1.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

2.  C1QTNF1-AS1 regulates the occurrence and development of hepatocellular carcinoma by regulating miR-221-3p/SOCS3.

Authors:  Hang Li; Bo Zhang; Meng Ding; Shang Lu; Hui Zhou; Dajun Sun; Gang Wu; Xianfeng Gan
Journal:  Hepatol Int       Date:  2019-05-08       Impact factor: 6.047

3.  Tumor suppressor action of liganded thyroid hormone receptor beta by direct repression of beta-catenin gene expression.

Authors:  Celine J Guigon; Dong Wook Kim; Xuguang Zhu; Li Zhao; Sheue-yann Cheng
Journal:  Endocrinology       Date:  2010-09-15       Impact factor: 4.736

4.  The TGFβ-induced lncRNA TBILA promotes non-small cell lung cancer progression in vitro and in vivo via cis-regulating HGAL and activating S100A7/JAB1 signaling.

Authors:  Zhiliang Lu; Yuan Li; Yun Che; Jianbing Huang; Shouguo Sun; Shuangshuang Mao; Yuanyuan Lei; Ning Li; Nan Sun; Jie He
Journal:  Cancer Lett       Date:  2018-06-15       Impact factor: 8.679

5.  Thyroid Hormone Receptor-β (TRβ) Mediates Runt-Related Transcription Factor 2 (Runx2) Expression in Thyroid Cancer Cells: A Novel Signaling Pathway in Thyroid Cancer.

Authors:  Frances E Carr; Phillip W L Tai; Michael S Barnum; Noelle E Gillis; Katherine G Evans; Thomas H Taber; Jeffrey H White; Jennifer A Tomczak; Diane M Jaworski; Sayyed K Zaidi; Jane B Lian; Janet L Stein; Gary S Stein
Journal:  Endocrinology       Date:  2016-06-02       Impact factor: 4.736

6.  PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer.

Authors:  Daniela De Martino; Emrullah Yilmaz; Arturo Orlacchio; Michela Ranieri; Ke Zhao; Antonio Di Cristofano
Journal:  Cancer Lett       Date:  2018-09-19       Impact factor: 8.679

7.  Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer.

Authors:  Francoise Borson-Chazot; Emmanuelle Dantony; Frederic Illouz; Jonathan Lopez; Patricia Niccoli; Johanna Wassermann; Christine Do Cao; Sophie Leboulleux; Marc Klein; Antoine Tabarin; Marie-Claude Eberle; Danielle Benisvy; Christelle de la Fouchardière; Claire Bournaud; Helene Lasolle; Armelle Delahaye; Muriel Rabilloud; Véronique Lapras; Myriam Decaussin-Petrucci; Martin Schlumberger
Journal:  Thyroid       Date:  2018-09       Impact factor: 6.568

8.  Hypothyroidism enhances tumor invasiveness and metastasis development.

Authors:  Olaia Martínez-Iglesias; Susana García-Silva; Javier Regadera; Ana Aranda
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

9.  Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.

Authors:  Xuguang Zhu; Li Zhao; Jeong Won Park; Mark C Willingham; Sheue-Yann Cheng
Journal:  Neoplasia       Date:  2014-09       Impact factor: 5.715

Review 10.  Emerging roles of long non-coding RNA in cancer.

Authors:  Anna Sanchez Calle; Yumi Kawamura; Yusuke Yamamoto; Fumitaka Takeshita; Takahiro Ochiya
Journal:  Cancer Sci       Date:  2018-06-28       Impact factor: 6.716

View more
  6 in total

1.  Ezh2 promotes TRβ lysine methylation-mediated degradation in hepatocellular carcinoma.

Authors:  Su Chan Park; Ji Min Lee
Journal:  Genes Genomics       Date:  2021-12-01       Impact factor: 1.839

2.  Common tumor-suppressive signaling of thyroid hormone receptor beta in breast and thyroid cancer cells.

Authors:  Eric L Bolf; Noelle E Gillis; Cole D Davidson; Lauren M Cozzens; Sophie Kogut; Jennifer A Tomczak; Seth Frietze; Frances E Carr
Journal:  Mol Carcinog       Date:  2021-09-17       Impact factor: 4.784

Review 3.  Thyroid receptor β might be responsible for breast cancer associated with Hashimoto's thyroiditis: a new insight into pathogenesis.

Authors:  Muskaan Dhingra; Shayon Mahalanobis; Asmita Das
Journal:  Immunol Res       Date:  2022-05-13       Impact factor: 4.505

4.  Regulation of cancer stem cell activity by thyroid hormone receptor β.

Authors:  Woo Kyung Lee; Xuguang Zhu; Sunmi Park; Yuelin Jack Zhu; Li Zhao; Paul Meltzer; Sheue-Yann Cheng
Journal:  Oncogene       Date:  2022-03-07       Impact factor: 8.756

5.  Case report: Lymph node metastases of breast cancer and thyroid cancer encountered in axilla.

Authors:  Rihan Li; Qingfu Zhang; Dongdong Feng; Feng Jin; Siyuan Han; Xinmiao Yu
Journal:  Front Oncol       Date:  2022-09-30       Impact factor: 5.738

6.  Thyroid Hormone Receptor Beta Inhibits PI3K-Akt-mTOR Signaling Axis in Anaplastic Thyroid Cancer via Genomic Mechanisms.

Authors:  Cole D Davidson; Eric L Bolf; Noelle E Gillis; Lauren M Cozzens; Jennifer A Tomczak; Frances E Carr
Journal:  J Endocr Soc       Date:  2021-06-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.